Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
Publication
, Conference
Ross, HJ; Kozono, DE; Urbanic, JJ; Williams, TM; Dufrane, C; Bara, I; Gandhi, M; Schulze, K; Brockman, JM; Wang, XF; Vokes, EE; Stinchcombe, T
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS8585 / TPS8585
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ross, H. J., Kozono, D. E., Urbanic, J. J., Williams, T. M., Dufrane, C., Bara, I., … Stinchcombe, T. (2018). Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. In Journal of Clinical Oncology (Vol. 36, pp. TPS8585–TPS8585). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585
Ross, Helen J., David E. Kozono, James John Urbanic, Terence Marques Williams, Carter Dufrane, Ilze Bara, Mayank Gandhi, et al. “Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.” In Journal of Clinical Oncology, 36:TPS8585–TPS8585. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps8585.
Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, et al. Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS8585–TPS8585.
Ross, Helen J., et al. “Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS8585–TPS8585. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps8585.
Ross HJ, Kozono DE, Urbanic JJ, Williams TM, Dufrane C, Bara I, Gandhi M, Schulze K, Brockman JM, Wang XF, Vokes EE, Stinchcombe T. Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS8585–TPS8585.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS8585 / TPS8585
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences